KALRAY
Kalray (Euronext Growth Paris: ALKAL), a leader in hardware and software technologies dedicated to data management and data intensive processing from cloud to edge, today announced a strategic collaboration with Arm to deliver ultra-high performance data processing and AI capabilities across a broad set of applications, leveraging Kalray’s industry leading data processing unit (DPU) technology and Arm’s robust partner ecosystem.
The ever-increasing demand for advanced data processing and AI capabilities has become a cornerstone of modern applications, ranging from storage and networking appliances to data center servers and edge computing, such as smart vision systems or telecom solutions.
This diverse application spectrum requires innovative solutions that can manage increasing data and processing requirements while delivering peak performance and high levels of power and cost efficiency. The combination of Kalray’s advanced AI and data processing acceleration capabilities paired with the broad Arm partner ecosystem will make high performance solutions for hardware and software developers across global enterprises more accessible.
In practical terms, this collaboration translates into Kalray integrating Arm® Neoverse™ Coherent Mesh Network (CMN) interconnect technology into Kalray’s next generation data processing and AI accelerator chiplet (code named “Dolomites”). This will enable the connection of Kalray’s DPU to Arm-based chiplets1 using the Arm CMN interconnect, delivered in the same package. It’s an innovative approach that optimizes flexibility, performance, power consumption, and cost efficiency; and it’s aimed at opening new horizons for a wide ecosystem of software developers, enabling them to leverage Kalray’s advanced processor capabilities to drive innovation across multitudes of applications.
“We couldn’t be more thrilled to collaborate with Arm and to bring the unique AI and data intensive processing capabilities offered by our DPU technology to the global Arm ecosystem,” said Eric Baissus, Kalray CEO. “This is a visionary step towards shaping the future of AI processing, making it more accessible, efficient, and powerful for a wider range of applications."
“AI is becoming integral to the entire compute infrastructure, driving an insatiable demand for more data and more computing power,” said Dermot O’Driscoll, vice president of product solutions, Infrastructure Line of Business, Arm. “By leveraging Arm’s CMN interconnect technology, Kalray is making its data acceleration solutions accessible across Arm’s global ecosystem and we look forward to this collaboration sparking new and impactful innovation for the era of AI.”
“This announcement maps to our expectation of increasing data processing solutions that address the expanding set of AI workloads,” said Howard Holton, chief technology officer, GigaOm. “The combination of Arm’s unique ecosystem and Kalray’s innovative DPU technology has the potential to bring the best of two worlds together at a time when the market has an insatiable appetite for data intensive processing.”
ABOUT KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets, from cloud to edge.
Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented data processing unit (DPU) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, media & entertainment, life sciences, scientific research, edge computing, automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
ABOUT ARM
Arm technology is building the future of computing. Its energy-efficient processor designs and software platforms have enabled advanced computing in more than 270 billion chips and its technologies securely power products from the sensor to the smartphone and the supercomputer. Together with 1,000+ technology partners, Arm is enabling artificial intelligence to work everywhere, and in cybersecurity, it is delivering the foundation for trust in the digital world – from chip to cloud. The future is being built on Arm.
1 A chiplet is a discrete unpackaged die that can be assembled into a package with other chiplets and assembled into a single processor chip. This new approach enables the development of processors that combine multiple chiplets, offering gains in flexibility and efficiency compared to traditional approaches.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207386465/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FIM Partners and Loomis Sayles Announce Transition of Global Emerging Market Equities Team6.11.2025 14:00:00 CET | Press release
FIM Partners today announced it has entered into an agreement with Loomis, Sayles & Company, to acquire the Global Emerging Market Equities (GEM) investment team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106799715/en/ Overview of the GEM Team and FIM Led by Ashish Chugh, Portfolio Manager and Head of Global Emerging Market Equities, the GEM Team follows a high conviction investment philosophy anchored in deep, fundamental research and a private equity-style approach to diligence and ownership. The team invests in high quality companies and those transitioning toward higher quality, leveraging its proprietary insights to identify long-term value creation opportunities across emerging markets. With an active, bottom-up, benchmark-agnostic strategy, the team builds high-conviction, concentrated, quality-focused portfolios that reflect a true ownership mindset. Founded in 2008, FIM Partners is a leading asset manager fo
IFCO’s circular model delivers global impact: Five years of progress marked with 2025 ESG report6.11.2025 14:00:00 CET | Press release
Over 10 billion single-use boxes replaced with reusable packaging in global fresh grocery supply chains IFCO, a global leader in reusable packaging containers (RPCs) for fresh food, today published its ESG Report 2025, marking the successful completion of its five-year sustainability strategy, Thriving in the Circular Economy. Over the last five years, IFCO has advanced every one of its 18 ESG goals, delivering measurable progress for the planet, people, partners, and customers while laying the groundwork for the next iteration of its sustainability objectives. The ESG Report 2025 confirms IFCO’s position as a global leader in circular packaging and highlights the role of reuse in addressing some of the sector’s most pressing challenges. Since IFCO’s founding in 1992, it has dedicated itself to eliminating packaging and food waste in the fresh grocery supply chain, enhancing efficiencies across the value chain and sharing the resulting long-term value with stakeholders. With operations
Debiopharm Takes a Step Forward for Children With CPP: Enrollment Completion for the Phase III Trial Evaluating the First Ever Yearly Injectable Triptorelin Formulation6.11.2025 14:00:00 CET | Press release
LIBELULATM trial completed enrollment of Central Precocious Puberty (CPP) patients in North and South America, advancing the path for Debio 4326, a triptorelin injectable 12-month extended-release formulation Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality of life, today announced the successful completion of patient enrollment in its open-label, single-arm, multi-center Phase III study (NCT06129539) ‘A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULATM)’. The completion of enrollment is a significant milestone for the development of Debio 4326, a unique injectable, biodegradable 12-month extended-release formulation of the established treatment, triptorelin. The LIBELULATM trial is being conducted across the United States, Argenti
U.K. Continues to Lead Europe in Shareholder Activism with 44% Year-on-Year Surge, According to Diligent Market Intelligence6.11.2025 13:00:00 CET | Press release
As the U.K. Market Fuels Growing Interest from Domestic and International Activists, Investors Have Adapted their Approach to Gain Access to Boardrooms in Germany and Italy The U.K. remains Europe’s most active market for shareholder activism, with a 44% year-on-year increase in targeted companies, according to the Corporate Governance in Europe 2025report by Diligent Market Intelligence (DMI). Between September 2024 and August 2025, 52 U.K. companies faced activism, compared to 36 over the same timeframe in 2024, underscoring the market’s heightened shareholder engagement. “The U.K. remains the primary driver of public-facing engagement in Europe, with other European markets increasingly witnessing similar strategies when behind-the-scenes efforts fail,” said Josh Black, Editor-in-Chief, Diligent Market Intelligence. “Activism in Europe runs the full gamut from hostile media campaigns to more private engagements but there is no doubt that boards should prepare for anything in what loo
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates6.11.2025 12:00:00 CET | Press release
Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024Global BRUKINSA® (zanubrutinib) revenues increased 51% to $1.0 billion versus third quarter 2024Diluted GAAP Earnings per American Depository Share (ADS) of $1.09, non-GAAP diluted Earnings per ADS of $2.6547 abstracts accepted at American Society of Hematology (ASH) Annual Meeting BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. “These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,” said John V. Oyler, Co-Founder, Chairman and CEO at BeOne. “BRUKINSA is now the global revenue leader in the BTKi class, supported by long-term efficacy and safety data and a growing body of evidence reinforcing its scientific hypothesis of sustained BTK inhibition. Our late-stage hematology portfolio continues
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom